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Objectives: The two most common breast reduction techniques presently used 
in North America are the Vertical Scar Reduction (VSR) and the Inverted T-shaped 
Reduction (ITR). A previous Randomized Controlled Trial (RCT) has shown no clear 
superiority of one over the other in terms of Health-Related Quality of Life (HRQL). 
No economic evaluation has been undertaken however to determine if the VSR 
is more cost-effective than the ITR. MethOds: 255 patients were randomized to 
either VSR or ITR immediately pre-operatively. The effectiveness of two techniques 
was measured with the HUI3. Both direct and productivity costs were captured 
parallel to the RCT. Case Report Forms (CRF) captured patient-related costs associ-
ated with the surgery. The human capital method was used to capture productiv-
ity losses. The perspectives of the Ministry of Health (MOH), the patient and the 
Society were considered Results: ITR dominated VSR under the MOH perspective 
by being slightly less costly ($3,090.06 vs. $3,106.58) and slightly more effective i.e. 
0.87 Quality Adjusted Life Years (QALY) versus 0.86 QALYs. In the societal and patient 
perspective, VSR was both less costly and less effective. At the commonly quoted 
Canadian threshold of $50,000 per QALY gained, the probability that VSR was cost-
effective was 29.3%, 68.2% and 66.9% under a MOH, patient and societal perspective 
respectively. A subgroup analysis of breast reductions of < 500 grams found that 
the VSR was more likely cost-effective. cOnclusiOns: This analysis informs us 
that the VSR is more likely than not, cost-effective from the patient and societal 
perspective but not from the MOH at a willingness-to-pay threshold of $50,000/
QALY. If, however, we were to limit the VSR for those breast reductions in which we 
expect excision of breast tissue < 500 grams per breast, then this technique is more 
likely cost-effective under all perspectives.
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Objectives: Estimate the incremental cost-effectiveness ratio (ICER) of D+T 
versus vemurafenib and dacarbazine for BRAFV600 mutation-positive MM from 
the UK NHS perspective. MethOds: A partitioned-survival model with 3 states 
(progression-free survival [PFS], post-progression survival, and death) and a 
lifetime horizon was developed. Treatment benefits were measured as gains in 
quality-adjusted life-years (QALYs). PFS and overall survival (OS) were derived 
from indirect treatment comparisons (ITCs) of D+T (from the Phase II BRF113220 
study) versus vemurafenib (BRIM-3) and dacarbazine (BREAK-3). Latest OS data 
were adjusted for confounding effects of treatment switching, permitted upon 
progression in all studies. Safety data were from aforementioned trials. Costs were 
from the literature, a physician survey, and assumptions. Costs of medications 
to the NHS (incorporating available patient-access schemes), post-study antican-
cer therapy, routine and adverse event (AE) management, treatment initiation, 
and death were included. Utility data for D+T were derived from BREAK-3, with 
adjustment for differences in response and incidence of AEs. Deterministic and 
probabilistic sensitivity analyses were performed. Results: ITCs showed D+T 
significantly improved PFS versus vemurafenib (hazard ratio [HR] 0.38; 95% CI, 
0.19–0.74) and dacarbazine (0.14; 0.08–0.28) and suggested improved OS, although 
not statistically significant (0.42; 0.09–1.97 versus vemurafenib and 0.26; 0.05–1.27 
versus dacarbazine). Treatment with D+T was associated with a gain in QALYs 
versus vemurafenib and dacarbazine. The ICER for D+T was £50,603/QALY versus 
vemurafenib and £49,804/QALY versus dacarbazine. cOnclusiOns: Based on 
results of a Phase II trial and an ITC, D+T offers improved PFS and OS versus vemu-
rafenib and dacarbazine. Further, considering NICE’s criteria for life-extending, 
end-of-life treatments, D+T may be cost-effective compared with vemurafenib, 
the NHS’s current standard of care for patients with BRAFV600 mutation-positive 
MM, although conclusions must await ongoing modelling on the basis of the Phase 
III, COMBI-D trial.
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Objectives: Muscle-invasive bladder cancer (MIBC) is a deadly disease that dis-
proportionately affects the elderly and is treated with bladder removal (i.e. radical 
cystectomy). A novel therapy utilizing chemo-radiation has demonstrated fewer 
adverse effects with comparable survival rates, with the possibility of requiring 
delayed cystectomy. The objective of this study was to examine the cost-utility of 
radical cystectomy compared to chemo-radiation in the treatment of (MIBC) among 
the elderly. MethOds: A decision-analytic model from the Medicare payer perspec-
tive followed hypothetical patients ages 65 and older with MIBC, using a 5-year 
time horizon from the start of treatment. Surgery and chemo-radiation toxicity, 
survival, and quality-of-life weights were derived from the clinical literature, and 
costs were derived from 2013 Medicare fee schedules. Sensitivity analyses were per-
formed to address the uncertainty of parameter values. Results: In the base-case 
analysis, chemo-radiation was less costly and less effective than radical cystectomy. 
Chemo-radiation resulted in a cost savings of $6,788 per patient whereas cystectomy 
resulted in additional 1.2 quality-adjusted life-years (QALY) per patient. Thus, cys-
tectomy would be preferred with an incremental cost-effectiveness ratio of $5,680 
per QALY. Therefore, at a threshold of $50,000 per QALY, chemo-radiation is not 
cost-effective when compared to radical cystectomy. Overall conclusions remained 
the same in sensitivity analyses, although the model was most dependent on the 
eases including cervical intraepithelial neoplasia grades 1 (CIN 1), grades 2 and 3 
(CIN 2/3), and cervical cancer. MethOds: A mathematical model of the transmis-
sion dynamics of HPV infection and disease for the HPV9 vaccine was calibrated 
to Japanese epidemiological data on cervical cancer. Based on global estimates, 
we attributed 70% of cervical cancer to HPV 16 and 18 for the quadrivalent vaccine 
(types 6/11/16/18: HPV4), and 20% to the five additional types in HPV9 (31, 33, 45, 
52, and 58). Other inputs were from public data sources and published literature. 
Vaccine efficacy against the 5 additional HPV types was taken from phase III trial 
results for the HPV9 vaccine. We assessed the incremental public health impact 
of HPV9 over HPV4 based on vaccinating 80% of females by age 12. Results: We 
projected that HPV9 vaccination of females could reduce the incidence of cervical 
cancer by 46% over 100 years, relative to 36% for HPV4. HPV9 vaccination relative to 
HPV4 vaccination could prevent an additional 305,000 cases of CIN1, 636,000 cases 
of CIN2/3, and 78,000 cases of cervical cancer in the Japanese population, cumula-
tive over 100 years. cOnclusiOns: Protecting the Japanese population against 
HPV infection with an HPV9 vaccination program relative to an HPV4 vaccination 
program can have significant public health benefits in addition to the benefits 
provided by HPV4 vaccination.
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Objectives: To assess cost-effectiveness of five standardized procedures for breast 
reconstruction to delineate the best reconstructive approach in the post mastectomy 
patients in the settings of non-radiated and radiated chest walls. MethOds: A decision 
tree modeled five breast reconstruction procedures from the provider perspective to 
evaluate cost-effectiveness. Procedures included autologous flaps with pedicled tissue, 
autologous flaps with free tissue, latissimus dorsi flap with breast implant, expander 
with implant exchange, and immediate implant placement. All methods were com-
pared to a do-nothing alternative. Data for model parameters was collected through a 
systematic review, and patient health utilities were calculated from an ad-hoc survey of 
reconstructive surgeons. Results were measured in cost (US $2011) per quality-adjusted 
life year (QALY). Univariate sensitivity analyses and Bayesian multivariate probalistic 
sensitivity analysis were conducted. Results: Pedicled and free autologous tissue 
reconstruction were cost-effective compared to the do-nothing alternative. Pedicled 
autologous tissue was the slightly more cost-effective of the two. The other procedures 
were not found to be cost-effective. The results were robust to a number of sensitivity 
analyses, although the margin between pedicled and free autologous tissue reconstruc-
tion is small and affected by some parameter values. cOnclusiOns: Autologous pedi-
cled tissue was slightly more cost-effective than free tissue reconstruction in radiated 
and non-radiated patients. Implant-based techniques were not cost-effective. This is 
in agreement with the growing trend at academic institutions to encourage autologous 
tissue reconstruction due to its natural recreation of the breast contour, suppleness, 
and resiliency in the setting of radiated recipient beds.
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Objectives: To the best of our knowledge, till date, US do not market any biosimilar 
for the treatment of chemotherapy induced febrile neutropenia (CIN). With Europe 
and Asia already marketing their biosimilars, it was timely to estimate the value of 
this proposed biosimilar in the US. The primary goal of this comparative technology 
assessment was to estimate the economic value by quantifying the savings offered 
by the biosimilar compared to its reference biological, filgrastim. The secondary goal 
was to highlight the clinical value of a proposed biosimilar with the help of a cost-
effectiveness analysis from a US payer perspective. The biosimilar is compared to 
filgrastim and pegfilgrastim, intended for the treatment of CIN. MethOds: A decision 
analytical model was designed and implemented using TreeAge Pro 2013 software. 
The initial cost and clinical estimates were based on a similar model published by 
Eldar-Lissai et al (2008) with modified and updated clinical estimates along with costs 
adjusted to 2013. The model was modified to include a proposed biosimilar expected 
to be released in the U.S. in 2014. Sensitivity analyses, including Monte Carlo probabil-
istic analyses, were conducted to assess the robustness of the model. Results: The 
model estimated expected costs for the three therapies to be: $3,092.41, $3,808.81, and 
$5,238.82 for biosimilar filgrastim, originator filgrastim, and pegfilgrastim respectively. 
The estimated savings of the biosimilar is estimated to be $ 716.40 per chemotherapy 
cycle and as per estimated usage, this translates to a total potential savings of $1.2 
billion by the end of 2014. The cost-effectiveness analysis resulted in an ICER of $ 
-3,766.29/day length of stay between biosimilar filgrastim and pegfilgrastim dem-
onstrating clinical value. cOnclusiOns: With the new US biosimilar legislation of 
February 2012 and filgrastim losing its patent protection in December 2013, this phar-
macoeconomic analysis is timely and significant for health policy.
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